Global biotechnology firm Biogen, Inc. reported Friday a profit for the second quarter that grew 30 percent from last year, reflecting lower charges and revenue growth amid increased sales of multiple sclerosis drug Tecfidera. Adjusted earnings per share topped analysts’ expectations, while quarterly revenues missed their estimates. The company also trimmed its full-year 2015 outlook.